FDA Approves Zuranolone for Postpartum Depression
The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.
Stay updated with breaking news from New Data Presented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.
New Data Presented on the Neovasc Reducer in Patients With Microvascular Disease Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 20, 2022) - Neovasc Inc. (NASDAQ: NVCN)
New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy...